Olanzapine versus placebo and haloperidol: Quality of life and efficacy results of the North American double-blind trial

Neuropsychopharmacology

Volumn 18, Issue 1, 1998, Pages 41-49

  Hamilton, Susan H ^a   Revicki, Dennis A ^b   Genduso, Laura A ^a   Beasley Jr , Charles M ^a  

^a ELI LILLY AND COMPANY   (United States)

^b UNITED BIOSOURCE CORPORATION   (United States)

Author keywords

Antipsychotic agents; Double blind method; Haloperidol; Quality of life; Schizophrenia

Indexed keywords

BENZATROPINE; HALOPERIDOL; LORAZEPAM; NEUROLEPTIC AGENT; OLANZAPINE; PLACEBO;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SCHIZOPHRENIA; SYMPTOM; TREATMENT OUTCOME;

EID: 0031905314     PISSN: 0893133X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0893-133X(97)00111-5     Document Type: Article

References (29)

1. American Psychiatric Association (1987): Diagnostic and Statistical Manual of Mental Disorders 3rd ed. revised (DSM-III-R). Washington, DC, American Psychiatric Association.
2. Andreasen NC Negative symptoms in schizophrenia. Definition and reliability Arch Gen Psychiatry. 39:1982;784-788.
3. Awad AG, Voruganti L, Heslegrave RJ Measuring quality of life in patients with schizophrenia. PharmacoEconomics. 11(1):1997;32-47.
4. Awad AG Quality of life of schizophrenia patients on medications and implications for new drug trials. Hosp Community Psychiatry. 43:1992;262-265.
5. Beasley CM, Tollefson G, Tran P, Satterlee W, Sanger T, Hamilton S Olanzapine versus placebo and haloperidol. Acute phase results of the North American double-blind olanzapine trial Neuropsychopharmacology. 14(2):1996;111-123.
6. Beasley CM Jr., Sanger T, Satterlee W, Tollefson G, Tran P, Hamilton S Olanzapine versus placebo. Results of a double-blind, fixed-dose olanzapine trial Psychopharmacology. 124:1996;159-167.
7. Becker M, Diamond R, Sainfort F A new patient focused index for measuring quality of life in persons with severe and persistent mental illness. Quality Life Res. 2:1993;239-251.
8. Bellack AS, Morrison RL, Wixted JT, Mueser KT An analysis of social competence in schizophrenia. Br J Psychiatry. 156:1990;809-818.
9. Breier A, Buchanan RW, Kirkpatrick B, Davis OR, Irish D, Summerfelt A, Carpenter WT Effects of clozapine on positive and negative symptoms in outpatients with schizophrenia. Am J Psychiatry. 151:1994;20-26.
10. Carpenter WT, Hanlon TE, Heinrichs DW, Summerfelt AT, Kirkpatrick B, Levine J, Buchanan RW Continuous versus targeted medication in schizophrenic outpatients. Outcome results Am J Psychiatry. 147:1990;1138-1148.
11. Carpenter WT, Heinrichs DW, Hanlon TE Methodologic standards for treatment outcomes research in schizophrenia. Am J Psychiatry. 138:1981;465-471.
12. Chouinard G, Jones B, Remington G, Bloom D, Addington D, MacEwan GW, Labelle A, Beauclair L, Arnott W A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients. J Clin Psychopharmacol. 13:1993;25-40.
13. Collins EJ, Hogan TP, Himansu D Measurement of therapeutic response in schizophrenia. A critical survey Schizophr Res. 5:1991;249-253.
14. Guy W ECDEU Assessment manual for psychopharmacology. 1976;National Institute of Mental Health, Publication ADM 76-338. Rockville, MD. U.S. Department of Health, Education, and Welfare.
15. Heinrichs DW, Hanlon TE, Carpenter WT The quality of life scale. An instrument for rating the schizophrenic deficit syndrome Schizophr Bull. 10:1984;388-398.
16. Kane J, Honigfeld G, Singer J, Meltzer H Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine Arch Gen Psychiatry. 45:1988;789-796.
17. Kane J, Marder SR Psychopharmacologic treatment of schizophrenia. Schizophr Bull. 19:1993;287-302.
18. Lehman AF, Postrado LT, Rachuba LT Convergent validation of quality of life assessments for persons with severe mental illness. Quality Life Res. 2:1993;327-333.
19. Lehman AF, Burns BJ Severe mental illness in the community. Spilker B Quality of Life Assessments in Clinical Trials. 1990;Raven Press, New York.
20. Lehman AF, Possidente S, Hawker F The quality of life of chronic patients in a state hospital and in community residences. Hosp Community Psychiatry. 37(9):1986;901-907.
21. Marder SR, Meibach RC Risperidone in the treatment of schizophrenia. Am J Psychiatry. 151:1994;825-835.
22. Meltzer HY, Burnett S, Bastani B, Ramirez LF Effects of six months of clozapine treatment on the quality of life of chronic schizophrenic patients. Hosp Community Psychiatry. 41:1990;892-897.
23. Moore NA, Calligaro DO, Wong DT, Bymaster F, Tye NC The pharmacology of olanzapine and other new antipsychotics. Curr Opinion Investigational Drugs. 2:1993;281-293.
24. Moore NA, Tupper DE, Hotten TM Olanzapine. Drugs Future. 19:1994;114-117.
25. Mueser K, Douglass M, Bellack A, Morrison R Assessment of enduring deficit and negative symptom subtypes in schizophrenia. Schizophr Bull. 17:1991;565-582.
26. Patrick D, Erickson P Health Status and Health Policy. Quality of Life in Health Care Evaluation and Resource Allocation:1993;Oxford University Press, New York. p 478.
27. Revicki DA, Murray MI Assessing health-related quality of life outcomes of drug treatments for psychiatric disorders. CNS Drugs. 1:1994;465-476.
28. Tollefson GD, Beasley CM, Tran PV, Street JS, Krueger JA, Tamura RN, Graffeo KA, Thieme ME Olanzapine versus haloperidol in the treatment of schizophrenia, schizoaffective and schizophreniform disorders. Results of an intentional collaborative trial Am J Psychiatry. 154:1997;457-465.
29. Woerner MG, Mannuza S, Kane JM Anchoring the BPRS. An aid to improved reliability Psychopharmacol Bull. 24:1988;112-117.